LY 354740
(Synonyms: (1S,2S,5R,6S)-2-氨基二环[3.1.0]己烷-2,6-二羧酸,LY354740; Eglumetad) 目录号 : GC10605An agonist of mGluR2 and mGluR3
Cas No.:176199-48-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Mice[1]In Experiment 1A wild-type (female: N=6; male: N=5) and Gria1−/− mice (female: N=7; male: N=8) first receive 30 trials of drug-free testing (five trials per day for 6 days). Each animal is then tested on rewarded alternation following an injection of either Eglumegad (LY354740) (15 mg/kg) or vehicle. After injection animals are returned to the home cage for 30 min before behavioural testing commenced. Each animal is given 10 trials of rewarded alternation in the T-maze. Mice are given a maximum of 120 s to a complete a trial. At least 24 h after the first round of drug testing the animals are re-tested in the absence of any drug treatment to ensure that there are no long-term effects of the drug, and that the mice maintain a high level of alternation performance. Twenty-four hours after this re-testing, mice receive a further 10 trials of rewarded alternation testing, but now under the drug condition that they have not previously received. The order of drug exposure is counterbalanced within genotype and sex as far as possible given the numbers of mice. In all stages, the number of trials in which the animal alternated, as well as time taken to run from the start arm to the food well on the sample run (sample latency), and the time taken to run from the start arm to making a choice on the choice run (choice latency), are recorded. Latencies are measured by the experimenter using a stopwatch. The experimenter is blind to the genotype and drug allocations of the animals throughout testing. In Experiment 1B, separate groups of male wild-type (N=7) and Gria1−/− mice (N=7) undgo the same procedure as Experiment 1A but now they receive either vehicle or a higher dose of Eglumegad (LY354740) (30 mg/kg). Subsequently, in Experiment 1C, to investigate the potential effects of increased proactive interference, the procedure used in Experiment 1B is repeated in the same mice, using the same drug dose (30 mg/kg), but now using a modified testing protocol in which the interval between trials is reduced to 20 s. Rats[4]Two experiments are conducted. The first experiment compares the effects of LY354740 (10 mg/kg, i.p., neutralized to a pH ~ 7.4) or vehicle (0.9% saline neutralized to pH ~ 7.4) in rats remaining in their home cages or rats exposed to 2 h of immobilization stress in plastic cones (n=7, cage control/vehicle; n=7, cage control/LY354740; n=6, stress/vehicle; n=6, stress/Eglumegad (LY354740)). The second experiment compares two lower LY354740 doses (1 and 3 mg/kg, i.p.) or vehicle in rats exposed to a 2-h period of immobilization stress to rats treated with vehicle in their home cages (n=4 for all groups). All animals are injected with either Eglumegad (LY354740) or vehicle 15 min prior to being placed in plastic cones with the open end securely closed. All immobilized rats are placed in plexiglass chamber with animal bedding on the bottom; brought to a quiet room outside of the animal colony; and immediately placed in a plastic cone. Two hours after being placed in the plastic containers, the rats are decapitated. The brains are removed and frozen on dry ice, and stored at −80°C. |
References: [1]. Boerner T, et al. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. Eur J Neurosci. 2017 Apr;45(7):912- |
Eglumegad (LY354740) down-regulates spots 1014, 1822 (hypoxia up-regulated protein 1), 4513 (an isoform of protein disulfide isomerase 3), 6204, 6312, 7306 (26S proteasome non-ATPase regulatory subunit 7) and protein spots 1013 and 6005 (destrin), and up-regulates spot 6507 (collapsin response mediator protein 1) in mouse cortical neurons[2]
Eglumegad (LY354740) (15 or 30 mg/kg, i.p.) has no effect on spatial working memory performance in Gria1−/− or WT mice, and it has no effect on rewarded alternation testing with a short inter-trial interval in Gria1−/− and WT mice at concentration of 30 mg/kg. Eglumegad (LY354740) (15 or 30 mg/kg, i.p.) reduces spontaneous locomotor activity in wild-type and Gria1−/− mice[1]. Eglumegad (LY354740) (15 mg/kg, i.p.) dreases novelty-induced hyperlocomotion in naive GluA1-KO and pre-handled GluA1-KO males, but not in females. Eglumegad (LY354740) (15 mg/kg, i.p.) significantly reduces the increased c-Fos expression of GluA1-KO males to the level of WT males, but not in of females[3]. Eglumegad (LY354740) (10 mg/kg, i.p.) attenuates the immobilization stress-induced increase in BDNF mRNA expression in the rat mPFC[4].
Reference:
[1]. Boerner T, et al. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. Eur J Neurosci. 2017 Apr;45(7):912-
[2]. Orlando R, et al. Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740. Neuropharmacology. 2014
[3]. Procaccini C, et al. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740. Neuroscience. 2013 Oct 10;250:189-200
[4]. Lee Y, et al. The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression. Neurosci Lett. 2006 May 8;398(3):328-32.
Cas No. | 176199-48-7 | SDF | |
别名 | (1S,2S,5R,6S)-2-氨基二环[3.1.0]己烷-2,6-二羧酸,LY354740; Eglumetad | ||
化学名 | (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid | ||
Canonical SMILES | OC([C@@H]1[C@@H]2[C@H]1CC[C@]2(C(O)=O)N)=O | ||
分子式 | C8H11NO4 | 分子量 | 185.18 |
溶解度 | Soluble to 100 mM in 1eq. NaOH | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.4002 mL | 27.0008 mL | 54.0015 mL |
5 mM | 1.08 mL | 5.4002 mL | 10.8003 mL |
10 mM | 0.54 mL | 2.7001 mL | 5.4002 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。